All Patents in the Purple Book

Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.

Pat No.Expir.Patent Title, Tradenames & Claim Types
6716602Oct 31, 2021Metabolic rate shifts in fermentations expressing recombinant proteins
Claim Types: Process
Lucentis (Injection) (Intravitreal)
6805686May 6, 2023Autoinjector with extendable needle protector shroud
Claim Types: Device; Method of administration
Humira (Injection) (Subcutaneous)
6828121Jul 7, 2022Bacterial host strains
Claim Types: Bacterial strain; Process
Lucentis (Injection) (Intravitreal)
6921659Oct 16, 2023Protease-deficient cells
Claim Types: Bacterial strain; Process
Lucentis (Injection) (Intravitreal)
7070959Jun 16, 2023Modified chimeric polypeptides with improved pharmacokinetic properties
Claim Types: Nucleic Acid; Expression Vector; Process
Eylea (Injection) (Intravitreal)
7485704Mar 7, 2025Reducing protein A leaching during protein A affinity chromatography
Claim Types: Process
Avastin (Injection) (Intravenous)
8231876Apr 4, 2027Purified antibody composition
Claim Types: Product-by-process; Drug in a container
Humira (Injection) (Subcutaneous)
8383773Dec 13, 2023Protein product and method for reducing biomass-biomass interactions
Claim Types: Product-by-process
Lucentis (Injection) (Intravitreal)
8420081Jan 13, 2030Antibody formulations and methods of making same
Claim Types: Formulation; Product-by-process; Device; Drug in a container; Process
Humira (Injection) (Subcutaneous)
8460895Mar 10, 2029Method for producing recombinant proteins with a constant content of pCO.sub.2 in the medium
Claim Types: Process
Avastin (Injection) (Intravenous)
8512983Jan 3, 2031Production of proteins in glutamine-free cell culture media
Claim Types: Process; Cell culture medium
Avastin (Injection) (Intravenous)
8574869Jul 7, 2028Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)
8663945Sep 13, 2027Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
Claim Types: Process
Humira (Injection) (Subcutaneous)
8708968Jan 24, 2032Removal of needle shields from syringes and automatic injection devices
Claim Types: Device
Humira (Injection) (Subcutaneous)
8715664Jul 24, 2027Use of human TNF.alpha. antibodies for treatment of erosive polyarthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
8808700May 16, 2026Use of TNF alpha inhibitor for treatment of erosive polyarthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
8883156Apr 4, 2027Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
8889136Oct 9, 2027Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)
8895009Apr 4, 2027Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)
8906372Apr 4, 2027Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
8906373Jul 18, 2023Use of TNF-alpha inhibitor for treatment of psoriasis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
8906646Sep 13, 2027Fed-batch method of making human anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)
8911737Jun 5, 2022Methods of administering anti-TNF.alpha. antibodies
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
8911964Sep 13, 2027Fed-batch method of making human anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)
8916153Apr 4, 2027Purified antibody composition
Claim Types: Composition
Humira (Injection) (Subcutaneous)
8926975Jun 8, 2027Method of treating ankylosing spondylitis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
8961973Apr 11, 2025Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)
8961974Apr 11, 2025Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)
8974790Jun 5, 2022Methods of administering anti-TNF.alpha. antibodies
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)
8986693Apr 11, 2025Use of TNF.alpha. inhibitor for treatment of psoriasis
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)
8992926Jun 5, 2022Methods of administering anti-TNF.alpha. antibodies
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)
8999337Feb 6, 2031Methods for treating juvenile idiopathic arthritis by inhibition of TNF.alpha.
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
9061005Apr 11, 2025Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)
9062106Apr 26, 2032Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)
9067992Jul 18, 2023Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
9085618Mar 14, 2033Low acidic species compositions and methods for producing and using the same
Claim Types: Formulation; Method of use
Humira (Injection) (Subcutaneous)
9085619Nov 28, 2028Anti-TNF antibody formulations
Claim Types: Composition; Formulation
Humira (Injection) (Subcutaneous)
9085620Jul 18, 2023Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Claim Types: Method of administration; Process
Humira (Injection) (Subcutaneous)
9090688Apr 26, 2032Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)
9090689Jul 18, 2023Use of TNF.alpha. inhibitor for treatment of psoriasis
Claim Types: Method of administration; Process
Humira (Injection) (Subcutaneous)
9090867Sep 13, 2027Fed-batch method of making anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)
9096666Apr 4, 2027Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)
9102723Apr 4, 2027Purified antibody composition
Claim Types: Process; Product-by-process; Method of use
Humira (Injection) (Subcutaneous)
9150645May 13, 2033Cell culture methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)
9181337Mar 14, 2033Modulated lysine variant species compositions and methods for producing and using the same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)
9181572Mar 14, 2033Methods to modulate lysine variant distribution
Claim Types: Process
Humira (Injection) (Subcutaneous)
9187559Apr 11, 2025Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)
9222106Jun 4, 2028Enhanced expression and stability regions
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)
9234032Sep 13, 2027Fed-batch methods for producing adalimumab
Claim Types: Process
Humira (Injection) (Subcutaneous)
9254338May 22, 2032Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)
9266949May 13, 2033Low acidic species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)
9273132Apr 4, 2027Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
9284370Jun 10, 2028Methods for treating juvenile idiopathic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
9284371Sep 13, 2027Methods of producing adalimumab
Claim Types: Process
Humira (Injection) (Subcutaneous)
9290568Mar 14, 2033Methods to control protein heterogeneity
Claim Types: Process
Humira (Injection) (Subcutaneous)
9315574Apr 21, 2033Low acidic species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)
9328165Apr 4, 2027Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)
9334319Mar 14, 2033Low acidic species compositions
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)
9339610Jan 24, 2032Removal of needle shield from syringes and automatic injection devices
Claim Types: Device
Humira (Injection) (Subcutaneous)
9346879Mar 14, 2033Protein purification methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)
9359434Mar 14, 2033Cell culture methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)
9441035Apr 22, 2034Cell culture media and methods of antibody production
Claim Types: Process
Avastin (Injection) (Intravenous)
9487809Jan 13, 2032Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Process
Avastin (Injection) (Intravenous)
9499614Mar 14, 2034Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
Claim Types: Process
Humira (Injection) (Subcutaneous)
9499616Mar 14, 2033Modulated lysine variant species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)
9505834Apr 26, 2032Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)
9512216Apr 11, 2025Use of TNF.alpha. inhibitor
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
9522953Apr 26, 2032Low acidic species compositions and methods for producing and using the same
Claim Types: Drug in a container; Method of use
Humira (Injection) (Subcutaneous)
9546212Jun 5, 2022Methods of administering anti-TNF.alpha. antibodies
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
9550826Nov 14, 2034Glycoengineered binding protein compositions
Claim Types: Formulation
Humira (Injection) (Subcutaneous)
9624295Mar 31, 2031Uses and compositions for treatment of psoriatic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
9669069Jan 11, 2032Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)
9669093Jun 10, 2028Methods for treating juvenile idiopathic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)
9683033Apr 26, 2032Cell culture methods to reduce acidic species
Claim Types: Formulation; Method of use
Humira (Injection) (Subcutaneous)
9688775Dec 31, 2022System for antibody expression and assembly
Claim Types: Process
Lucentis (Injection) (Intravitreal)
9708400Mar 14, 2033Methods to modulate lysine variant distribution
Claim Types: Formulation
Humira (Injection) (Subcutaneous)
9714293Aug 5, 2030Production of proteins in glutamine-free cell culture media
Claim Types: Process
Avastin (Injection) (Intravenous)
9765379Mar 9, 2034Harvest operations for recombinant proteins
Claim Types: Process
Lucentis (Injection) (Intravitreal)
9795672May 27, 2024Treatment with anti-VEGF antibodies
Claim Types: Method of use
Avastin (Injection) (Intravenous)
9816110Oct 21, 2035CHO integration sites and uses thereof
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)
9856287Jun 21, 2030Refolding proteins using a chemically controlled redox state
Claim Types: Process
Neulasta (Injection) (Subcutaneous); Neulasta Onpro (Injection) (Subcutaneous)
9913902Apr 4, 2027Purified antibody composition
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)
9957318Apr 26, 2032Protein purification methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)
10011856May 25, 2031Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Cell culture
Avastin (Injection) (Intravenous)
10017732Mar 13, 2034Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)
10112994Nov 4, 2035Methods of producing two chain proteins in bacteria
Claim Types: Process
Lucentis (Injection) (Intravitreal)
10130681Jan 11, 2032Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)
10208355Jul 13, 2035Method of treatment for glioblastoma by administering a VEGF antagonist
Claim Types: Method of use
Avastin (Injection) (Intravenous)
10274466Jul 10, 2035Elucidation of ion exchange chromatography input optimization
Claim Types: Analytical procedure
Avastin (Injection) (Intravenous)
10336983Jul 30, 2035Method for increasing the specific production rate of eukaryotic cells
Claim Types: Process
Avastin (Injection) (Intravenous)
10406226Mar 22, 2026Method of manufacturing VEGF antagonist fusion proteins
Claim Types: Process
Eylea (Injection) (Intravitreal)
10415055Jun 4, 2028Enhanced expression and stability regions
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)
10421984Sep 18, 2033Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele
Claim Types: Process
Lucentis (Injection) (Intravitreal)
10464992Jun 14, 2027VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)
10513697Sep 16, 2032CO.sub.2 profile cultivation
Claim Types: Process
Avastin (Injection) (Intravenous)
10662237May 25, 2031Method to improve virus filtration capacity
Claim Types: Process
Avastin (Injection) (Intravenous)
10669594Feb 12, 2037Compositions and methods for detecting a biological contaminant
Claim Types: Analytical Method
Eylea (Injection) (Intravitreal)
10676710Mar 13, 2034Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous)
10704071Aug 17, 2031Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Vector
Avastin (Injection) (Intravenous)
10828345Jan 11, 2032Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)
10829732Mar 13, 2034Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)
10857205Jan 11, 2032Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)
10857231Disclaimer filed on March 14, 2022Formulations of VEG antagonist fusion proteins and method of manufacturing them
Claim Types: Formulation; Formulation claimed by its inherent performace characteristics; Process
Eylea (Injection) (Intravitreal)
10888601Jan 11, 2032Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Dosaage regimen
Eylea (Injection) (Intravitreal)
10905786Mar 6, 2038Sterilisation method
Claim Types: Process
Eylea (Injection) (Intravitreal)
10906934Oct 11, 2033Protein purification methods
Claim Types: Process
Avastin (Injection) (Intravenous)
10906986Jul 7, 2028Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Avastin (Injection) (Intravenous)
10918754Mar 6, 2038Sterilisation method
Claim Types: Process
Eylea (Injection) (Intravitreal)
10927342Aug 3, 2036Taurine supplemented cell culture medium and methods of use
Claim Types: Process
Eylea (Injection) (Intravitreal)
10973879May 17, 2039Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)
10982003Aug 6, 2030Production of proteins in glutamine-free cell culture media
Claim Types: Process
Avastin (Injection) (Intravenous)
11053280Aug 18, 2040Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)
11066458Jun 14, 2027VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)
11078294Jul 8, 2028Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Avastin (Injection) (Intravenous)
11083792Apr 4, 2027Purified antibody composition
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)
11084865Jun 14, 2027VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)
11104715Aug 18, 2040Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Claim Types: Process
Eylea (Injection) (Intravitreal)
11160918Jul 29, 2039Medical device packaging and related methods
Claim Types: Kit
Eylea (Injection) (Intravitreal)
11167030Nov 28, 2028Protein formulations and methods of making same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)
11174283Aug 18, 2040Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)
11186625Aug 18, 2040Anti-VEGF protein compositions and methods for producing the same
Claim Types: Composition; Product-by-process
Eylea (Injection) (Intravitreal)
11191834Nov 28, 2028Protein formulations and methods of making same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)
11253572Jan 11, 2032Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)
11299532Aug 18, 2040Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)
11306135Aug 18, 2040Anti-VEGF protein compositions and methods for producing the same
Claim Types: Composition; Product-by-process
Eylea (Injection) (Intravitreal)
11332771Mar 14, 2034Serum-free cell culture medium
Claim Types: Process
Eylea (Injection) (Intravitreal)
D858754Sep 3, 2034Syringe cap
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)
D906102Dec 29, 2035Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)
D934069Oct 26, 2036Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)